Beneath the brand new partnership, Samsung Biologics will develop and manufacture an antibody for a LegoChem Biosciences ADC candidate.
Samsung Biologics introduced on Feb. 7, 2024 that it has signed a partnership settlement with LegoChem Biosciences, a biotech firm centered on antibody-drug conjugate (ADC) applications, to develop and manufacture an antibody for an ADC candidate.
Beneath the deal, Samsung Biologics will present antibody improvement and drug substance manufacturing providers for LegoChem Biosciences’ ADC program for treating stable tumors. LegoChem Biosciences intends to submit an investigational new drug utility to FDA within the first half of 2025. In accordance with an organization press launch, non-clinical knowledge has proven promising efficacy outcomes.
Samsung Biologics is on monitor to including ADCs to its pipeline. The corporate expects to have a brand new standalone, devoted ADC facility—at the moment being constructed—to be operational inside 2024.
“Collaboration between Samsung Biologics and LegoChem Biosciences will allow us to ship on our frequent purpose to develop and manufacture environment friendly and secure therapeutics for sufferers,” stated John Rim, CEO and president of Samsung Biologics, within the press launch. “We sit up for working with LegoChem Biosciences to assist their pipeline of revolutionary ADC candidates and safe new alternatives within the fast-growing ADC area.”
“LegoChem Biosciences had beforehand provided antibodies for ADC by means of solely abroad firms, however we count on that we will safe a steady home provide chain by means of this contract,” stated Yong-Zu Kim, CEO and president of LegoChem Biosciences, within the launch.
Supply: Samsung Biologics